zidovudine has been researched along with barbital in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Anderson, LM; Diwan, BA; Haines, DC; Logsdon, D; Olivero, OA; Poirier, MC; Rice, JM; Riggs, CW; Yuspa, SH | 1 |
3 other study(ies) available for zidovudine and barbital
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice.
Topics: Animals; Animals, Newborn; Anti-HIV Agents; Barbital; Body Weight; Carcinogens; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Maternal-Fetal Exchange; Mice; Neoplasms, Experimental; Pregnancy; Survival Rate; Time Factors; Urogenital Neoplasms; Zidovudine | 1999 |